Alimera Sciences (ALIM) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 05, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ALIMERA SCIENCES INC
Entity Central Index Key	1,267,602
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		44,545,623

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash and cash equivalents	$ 39,340,000	$ 76,697,000
Accounts receivable, net	9,377,000	850,000
Prepaid expenses and other current assets	2,497,000	3,234,000
Inventory, net (Note 5)	1,716,000	1,734,000
Deferred financing costs	458,000	754,000
Total current assets	53,388,000	83,269,000
PROPERTY AND EQUIPMENT, net	2,587,000	1,653,000
INTANGIBLE ASSET, net (Note 6)	23,038,000	24,490,000
TOTAL ASSETS	79,013,000	109,412,000
CURRENT LIABILITIES:
Accounts payable	3,068,000	5,021,000
Accrued expenses (Note 7)	3,238,000	954,000
Accrued milestone payments	0	2,000,000
Outsourced services payable	213,000	1,466,000
Note payable (Note 9)	0	1,023,000
Capital lease obligations	218,000	11,000
Total current liabilities	6,737,000	10,475,000
NON-CURRENT LIABILITIES:
Derivative warrant liability	3,013,000	16,098,000
Note payable, net of discount — less current portion (Note 9)	34,448,000	33,065,000
Other non-current liabilities	$ 1,454,000	$ 255,000
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY:
Preferred stock
Common stock, $.01 par value — 100,000,000 shares authorized, 44,470,730 shares issued and outstanding at September 30, 2015 and 44,320,342 shares issued and outstanding at December 31, 2014	$ 445,000	$ 443,000
Additional paid-in capital	296,871,000	292,851,000
Common stock warrants	1,497,000	1,497,000
Accumulated deficit	(333,187,000)	(313,255,000)
Accumulated other comprehensive loss	(1,060,000)	(812,000)
TOTAL STOCKHOLDERS’ EQUITY	33,361,000	49,519,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	79,013,000	109,412,000
Series A convertible preferred stock
STOCKHOLDERS’ EQUITY:
Preferred stock	19,227,000	19,227,000
Series B convertible preferred stock
STOCKHOLDERS’ EQUITY:
Preferred stock	$ 49,568,000	$ 49,568,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	44,470,730	44,320,342
Common stock, shares outstanding	44,470,730	44,320,342
Series A convertible preferred stock
Preferred stock, shares authorized	1,300,000	1,300,000
Preferred stock, shares issued	600,000	600,000
Preferred stock, shares outstanding	600,000	600,000
Preferred stock, liquidation preference	$ 24,000,000	$ 24,000,000
Series B convertible preferred stock
Preferred stock, shares authorized	8,417	8,417
Preferred stock, shares issued	8,416.251	8,416.251
Preferred stock, shares outstanding	8,416.251	8,416.251
Preferred stock, liquidation preference	$ 50,750,000	$ 50,750,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
NET REVENUE	$ 6,901	$ 2,408	$ 16,615	$ 6,682
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(634)	(372)	(1,293)	(1,312)
GROSS PROFIT	6,267	2,036	15,322	5,370
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	4,078	4,145	11,222	8,840
GENERAL AND ADMINISTRATIVE EXPENSES	3,031	2,958	10,471	8,643
SALES AND MARKETING EXPENSES	6,949	3,476	21,003	9,763
DEPRECIATION AND AMORTIZATION	653	82	1,864	151
OPERATING EXPENSES	14,711	10,661	44,560	27,397
NET LOSS FROM OPERATIONS	(8,444)	(8,625)	(29,238)	(22,027)
INTEREST EXPENSE, NET AND OTHER	(1,317)	(408)	(3,590)	(862)
UNREALIZED FOREIGN CURRENCY LOSS, NET	(63)	(255)	(34)	(457)
CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY	8,363	2,324	13,085	(2,752)
LOSS ON EARLY EXTINGUISHMENT OF DEBT	0	0	0	(440)
NET LOSS BEFORE TAXES	(1,461)	(6,964)	(19,777)	(26,538)
PROVISION FOR TAXES	(82)	(45)	(155)	(114)
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS	$ (1,543)	$ (7,009)	$ (19,932)	$ (26,652)
NET LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS — Basic and diluted (in dollars per share)	$ (0.03)	$ (0.17)	$ (0.45)	$ (0.68)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and diluted	44,436,224	41,062,814	44,393,831	39,083,187

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS	$ (1,543)	$ (7,009)	$ (19,932)	$ (26,652)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	40	(197)	(248)	(175)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	40	(197)	(248)	(175)
COMPREHENSIVE LOSS	$ (1,503)	$ (7,206)	$ (20,180)	$ (26,827)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,932)	$ (26,652)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,864	151
Unrealized foreign currency transaction loss	34	457
Loss from early extinguishment of debt	0	440
Amortization of deferred financing costs and debt discount	524	261
Stock-based compensation expense	3,702	2,833
Change in fair value of derivative warrant liability	(13,085)	2,752
Changes in assets and liabilities:
Accounts receivable	(8,455)	(679)
Prepaid expenses and other current assets	627	1,307
Inventory	(88)	(9)
Accounts payable	(1,447)	1,341
Accrued expenses and other current liabilities	(828)	2,649
Other long-term liabilities	612	(2)
Net cash used in operating activities	(36,472)	(15,151)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(370)	(163)
Net cash used in investing activities	(370)	(163)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	278	709
Proceeds from sale of common stock	42	37,543
Payment of issuance cost of common stock	0	(2,389)
Payment of Series B Convertible Preferred Stock offering costs	(327)	0
Payment of principal on notes payable	0	(4,861)
Payment of debt extinguishment costs	0	(246)
Proceeds from issuance of notes payable	0	35,000
Payment of debt costs	0	(1,016)
Payment of capital lease obligations	(207)	(7)
Net cash (used in) provided by financing activities	(214)	64,733
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS	(301)	(623)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(37,357)	48,796
CASH AND CASH EQUIVALENTS — Beginning of period	76,697	12,628
CASH AND CASH EQUIVALENTS — End of period	39,340	61,424
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	2,904	502
Cash paid for income taxes	9	0
Supplemental schedule of non-cash investing and financing activities:
Property and equipment acquired under capital leases	$ 997	$ 0

Nature of Operations

Nature of Operations	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	NATURE OF OPERATIONS Alimera Sciences, Inc., and its subsidiaries (the Company), is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware. The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company’s management believes these diseases are not well treated with current therapies and represent a significant underserved market opportunity. The Company’s only commercial product is ILUVIEN ® , which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, and the United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in the EEA, the Company has committed to conduct a five -year, post-authorization, open label registry study of ILUVIEN in 800 patients. The Company launched ILUVIEN in the United Kingdom and Germany in the second quarter of 2013 and in Portugal and the U.S. in the first quarter of 2015.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (interim financial statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Article 10-01 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying interim financial statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2014 and related notes included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 13, 2015. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year. Reclassifications Within the unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2014, the Company reclassified certain medical affairs support expenses of $204,000 and $464,000 , respectively, from sales and marketing expenses to research, development and medical affairs expenses to conform to the current year presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2014. In addition, with the U.S. launch of ILUVIEN in the nine months ended September 30, 2015, the Company adopted the revenue recognition and segment reporting policies set forth below. Revenue Recognition In the U.S., the Company sells ILUVIEN to a limited number of specialty distributors who in turn sell the product downstream to pharmacies and physician practices. Revenue from U.S. product sales is recorded upon sale to the specialty distributors net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period’s net product sales. Government Rebates and Chargebacks: The Company estimates reductions to product sales for Medicaid and Veterans’ Administration (VA) programs, and for certain other qualifying federal and state government programs. Based upon the Company’s contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company’s liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company’s reserves related to discounted pricing to VA, Public Health Services, and other institutions (collectively qualified healthcare providers) represent the Company’s estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., specialty distributors). The Company’s customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company’s reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. Distribution-Related Fees: The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. Product Returns: Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product’s expiration date. The Company will accept returns for three months prior to and up to nine months after the product expiration date. Depending on the circumstances, the Company may provide replacement products or cash credit for returns. Product returned is generally not resalable given the nature of the Company’s products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers to healthcare providers using product-specific data provided by its customers. If necessary, the Company’s estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. Reporting Segments The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, the U.S. and International. Previously, the business was managed on an aggregate basis. As a result of the retrospective presentation and disclosure requirements under U.S. GAAP for changes in segment reporting, the Company is required to reflect the change in presentation and disclosure for all periods presented. As such, the Company has presented in Note 16, Segment Information, the financial results for the three and nine months ended September 30, 2014 in the same manner as for the three and nine months ended September 30, 2015. During the three and nine months ended September 30, 2015, two individual customers within the U.S. segment accounted for 73% and 68% of the Company's consolidated revenues. As of September 30, 2015, two individual customers within the U.S. segment accounted for 83% of the Company's accounts receivable balances. The accounting policies of these segments are the same as those described in Note 2, Summary of Significant Accounting Policies included in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K. Research and Development Expenses Research and development expenses were $940,000 and $1,082,000 for the three months ended September 30, 2015 and 2014, respectively and $1,958,000 and $3,480,000 for the nine months ended September 30, 2015 and 2014, respectively. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern . ASU 2014-15 provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted and the standard is to be retrospectively applied to all periods presented upon adoption. The Company is still evaluating the potential impact of adopting this guidance on its financial statements.

Factors Affecting Operations

Factors Affecting Operations	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Factors Affecting Operations	FACTORS AFFECTING OPERATIONS To date, the Company has incurred negative cash flow from operations, and has accumulated a deficit of $333,187,000 from inception through September 30, 2015 . As of September 30, 2015 , the Company had approximately $39,340,000 in cash and cash equivalents. The Company believes that it has sufficient funds available to fund its operations for the continued commercialization of ILUVIEN in the U.S., Germany, Portugal, and the United Kingdom. The Company does not expect to generate positive cash flow from operations until 2017, if at all. The Company may seek to raise additional financing to fund its working capital needs for the commercialization of ILUVIEN, the development and commercialization of future products and product candidates or in order to comply with certain financial covenants of the loan agreements. If the Company is unable to raise additional financing, then it may adjust its commercial plans so that it can continue to operate with its existing cash resources. The accompanying interim financial statements have been prepared assuming the Company will continue as a going concern. The Company’s negative cash flow from operations and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The interim financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	INVENTORY Inventory consisted of the following: September 30, 2015 December 31, 2014 (In thousands) Component parts (1) $ 153 $ 76 Work-in-process (2) 693 219 Finished goods 1,185 1,972 Total inventory 2,031 2,267 Inventory reserve (315 ) (533 ) Inventory — net $ 1,716 $ 1,734 (1) Component parts inventory consists of manufactured components of the ILUVIEN applicator. (2) Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible Assets	INTANGIBLE ASSETS As a result of the United States Food and Drug Administration's (the FDA) approval of the New Drug Application for ILUVIEN in September 2014, the Company was required to pay pSivida US, Inc. (pSivida) a milestone payment of $25,000,000 (the pSivida Milestone Payment) in October 2014 (see Note 8). The Company had no intangible assets prior to September 2014. The gross carrying amount of the intangible asset was $25,000,000 , which is being amortized over approximately 13 years from the acquisition date. The amortization expense related to the intangible asset was $489,000 and $1,451,000 for the three and nine months ended September 30, 2015, respectively. The amortization expense related to the intangible asset was $49,000 for both the three and nine months ended September 30, 2014. The net book value of the intangible asset was $23,038,000 and $24,490,000 as of September 30, 2015 and December 31, 2014, respectively. The estimated future amortization expense as of September 30, 2015 for the remaining periods in the next five years and thereafter is as follows (in thousands): Years Ending December 31 2015 $ 488 2016 1,940 2017 1,940 2018 1,940 2019 1,940 Thereafter 14,790 Total $ 23,038

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accrued Expenses	ACCRUED EXPENSES Accrued expenses consisted of the following: September 30, 2015 December 31, 2014 (In thousands) Accrued compensation expenses $ 1,718 $ 226 Accrued clinical investigator expenses 453 309 Accrued rebate, chargeback and other revenue reserves 402 — Other accrued expenses 665 419 Total accrued expenses $ 3,238 $ 954

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreements	LICENSE AGREEMENTS The Company entered into an agreement with pSivida for the use of fluocinolone acetonide (FAc) in pSivida’s proprietary delivery device in February 2005, which was subsequently amended in 2008. The agreement with pSivida provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN. The Company’s license rights to pSivida’s proprietary delivery device could revert to pSivida if the Company were to (i) fail twice to cure its breach of an obligation to make certain payments to pSivida following receipt of written notice thereof; (ii) fail to cure other breaches of material terms of its agreement with pSivida within 30 days after notice of such breaches or such longer period (up to 90 days ) as may be reasonably necessary if the breach cannot be cured within such 30 -day period; (iii) file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than 60 days ; or (iv) notify pSivida in writing of its decision to abandon its license with respect to a certain product using pSivida’s proprietary delivery device. The Company must share 20% of the net profits of ILUVIEN, determined on a cash basis, and 33% of any lump sum milestone payments received from a sub-licensee of ILUVIEN, as defined by the agreement with pSivida. In connection with this arrangement, the Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the agreement, incurred prior to product profitability out of pSivida’s share of net profits. As of September 30, 2015 and December 31, 2014 , the Company was owed approximately $19,997,000 and $12,956,000 , respectively, in commercialization costs. Due to the uncertainty of future net profits, the Company has fully reserved these amounts in the accompanying interim condensed consolidated financial statements. As a result of the FDA’s approval of the NDA for ILUVIEN in September 2014, the Company made the pSivida Milestone Payment of $25,000,000 in October 2014.

Loan Agreements

Loan Agreements	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Loan Agreements	LOAN AGREEMENTS 2013 Loan Agreement In May 2013, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (2013 Loan Agreement) with Silicon Valley Bank (SVB) to provide Limited with additional working capital for general corporate purposes. Under the 2013 Loan Agreement, SVB made a term loan (2013 Term Loan) in the principal amount of $5,000,000 to Limited and agreed to provide up to an additional $15,000,000 to Limited under a working capital line of credit (2013 Line of Credit). In April 2014, the 2013 Term Loan was repaid and the 2013 Line of Credit was terminated in connection with the 2014 Loan Agreement described below. Upon repayment of the 2013 Term Loan in April 2014, Limited paid SVB an outstanding loan balance prepayment penalty of $133,000 , and an early termination fee of $113,000 in connection with the termination of the 2013 Line of Credit. In addition, in accordance with ASC 470-50-40-17, the Company expensed the facility fee and incremental value of the warrants associated with the 2013 Term Loan as part of the loss on early extinguishment. 2014 Loan Agreement In April 2014, Limited entered into a loan and security agreement (2014 Loan Agreement) with Hercules Technology Growth Capital, Inc. (Hercules) providing for a term loan of up to $35,000,000 (2014 Term Loan). Under the 2014 Loan Agreement, Hercules made an advance in the initial principal amount of $10,000,000 to Limited at closing to provide Limited with additional working capital for general corporate purposes and to repay the 2013 Term Loan. Hercules made an additional advance of $25,000,000 to Limited in September 2014 following the approval of ILUVIEN by the FDA to fund the pSivida Milestone Payment. The 2014 Term Loan provided for interest only payments through November 2015. Interest on the 2014 Term Loan accrues at a floating per annum rate equal to the greater of (i) 10.90% , or (ii) the sum of (A) 7.65% , plus (B) the prime rate. Following the interest only period the 2014 Term Loan was due and payable to Hercules in equal monthly payments of principal and interest through May 1, 2018. In November 2015, Limited and Hercules amended the 2014 Term Loan to extend the interest only payments through May 2017. Beginning in June 2017, Limited will make eleven equal monthly payments of principal and interest based upon a 30 -month amortization schedule followed by a final payment of all remaining outstanding principal and interest in May 2018. In connection with the amendment, Limited paid to Hercules an amendment fee of $262,500 and agreed to make an additional payment of $1,050,000 equal to 3% of the 2014 Term Loan at the time of the final payment in May 2018. In accordance with ASC 470-10-45, Debt , the balance sheet as of September 30, 2015 reflect the amended debt maturities. In connection with the initial advance under the 2014 Term Loan, Limited paid to Hercules a facility charge of $262,500 and incurred legal and other fees of approximately $383,000 . Limited incurred approximately $375,000 in additional fees in connection with the second advance. If Limited repays the 2014 Term Loan, as amended, prior to maturity, it will pay Hercules a prepayment penalty of 1.25% of the total principal amount repaid. Limited and the Company, on a consolidated basis with its other subsidiaries, also agreed to customary affirmative and negative covenants and events of default in connection with these arrangements. The occurrence of an event of default could result in the acceleration of Limited’s obligations under the 2014 Term Loan, as amended, and an increase to the applicable interest rate, and would permit Hercules to exercise remedies with respect to the collateral under the 2014 Term Loan, as amended. Limited’s obligations to Hercules are secured by a first priority security interest in substantially all of Limited’s assets, excluding intellectual property. Hercules does, however, maintain a negative pledge on Limited’s intellectual property requiring Hercules’ consent prior to the sale of such intellectual property. The Company and certain of the Company’s other subsidiaries are guarantors of the obligations of Limited to Hercules under the 2014 Loan Agreement, as amended, pursuant to separate guaranty agreements between Hercules and each of Limited and such subsidiaries (Guaranties). Pursuant to the Guaranties, the Company and these subsidiaries granted Hercules a first priority security interest in substantially all of their respective assets excluding intellectual property. In connection with the amendment, Limited agreed to covenants regarding certain revenue thresholds and liquidity for the Company. As of September 30, 2015, the Company, on a consolidated basis with its subsidiaries, was in compliance with the covenants of the 2014 Term Loan. In connection with Limited entering into the 2014 Loan Agreement, the Company entered into a warrant agreement with Hercules to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share. Sixty percent of the warrants were exercisable at the closing in April 2014 and the remaining forty percent became exercisable upon the funding of the additional $25,000,000 to Limited in September 2014. Further, the Company agreed to amend the warrant agreement in connection with the amendment of the 2014 Loan Agreement to increase the number of shares issuable upon exercise to 660,377 and decrease the exercise price to $2.65 per share. Fair Value of Debt The weighted average interest rates of the Company’s notes payable approximate the rate at which the Company could obtain alternative financing; therefore, the carrying amount of the notes approximated their fair value at September 30, 2015 and December 31, 2014.

Loss Per Share (EPS)

Loss Per Share (EPS)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Loss Per Share (EPS)	LOSS PER SHARE (EPS) Basic EPS is calculated in accordance with ASC 260, Earnings per Share , by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants and convertible preferred stock. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Three Months Ended September 30, Nine Months Ended 2015 2014 2015 2014 Series A convertible preferred stock 9,022,556 9,022,556 9,022,556 9,022,556 Series B convertible preferred stock 8,416,251 — 8,416,251 — Series A convertible preferred stock warrants 4,511,279 4,511,279 4,511,279 4,511,279 Common stock warrants 362,970 362,970 362,970 362,970 Stock options 9,094,716 7,582,462 9,094,716 7,582,462 Total 31,407,772 21,479,267 31,407,772 21,479,267

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Preferred Stock	PREFERRED STOCK Series A Convertible Preferred Stock On October 2, 2012, the Company closed its preferred stock financing in which it sold units consisting of 1,000,000 shares of Series A Convertible Preferred Stock and warrants to purchase 300,000 shares of Series A Convertible Preferred Stock for gross proceeds of $40,000,000 , prior to the payment of approximately $560,000 of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October 1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company’s common stock at any time at the option of the holder at the rate equal to $40.00 divided by $2.66 (Conversion Price). The initial Conversion Price was subject to adjustment based on certain customary price based anti-dilution adjustments. These adjustment features lapsed in September 2014. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i) the Company receives and publicly announces the approval by the FDA of the Company’s NDA for ILUVIEN and (ii) the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a) shares of common stock or (b) other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than $10.00 and that results in total gross proceeds to the Company of at least $30,000,000 . The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company’s ability to declare or pay any dividend or distribution on any shares of capital stock. Each unit sold in the preferred stock financing included a warrant to purchase 0.30 shares of Series A Convertible Preferred Stock at an exercise price equal to $44.00 per share. At the election of the holder of a warrant, the warrant may be exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. These warrants are considered derivative instruments because the agreements provide for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future, and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. The warrant anti-dilution provisions lapsed in September 2014. At September 30, 2015 and December 31, 2014 , the fair market value of the warrants was estimated to be $3,013,000 and $16,098,000 , respectively. During the three months ended September 30, 2015 and 2014, the Company recorded gains of $8,363,000 and $2,324,000 , respectively, as a result of the change in fair value of the warrants. During the nine months ended September 30, 2015 and 2014, the Company recorded gain of $13,085,000 and a loss of $2,752,000 , respectively, as a result of the change in fair value of the warrants. In April 2014, 2,255,639 shares of common stock were issued pursuant to the conversion of 150,000 shares of Series A Convertible Preferred Stock held by an investor. In September 2014, 3,759,398 shares of common stock were issued pursuant to the conversion of 250,000 shares of Series A Convertible Preferred Stock held by another investor. As of September 30, 2015, there were 600,000 shares of Series A Convertible Preferred Stock issued and outstanding. Series B Convertible Preferred Stock On December 12, 2014, the Company closed a preferred stock financing in which it sold 8,291.873 shares of Series B Convertible Preferred Stock for a purchase price of $6,030 per share, or an aggregate purchase price of $50,000,000 , prior to the payment of approximately $432,000 of related issuance costs. The Company issued an additional 124.378 shares of Series B Convertible Preferred Stock as a subscription premium to the purchasers. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into 1,000 shares of the Company’s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company’s existing Series A Convertible Preferred Stock, and senior to the Company’s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock do not have voting rights. The Series B Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. The Company determined that the conversion option of the Preferred Shares represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of $750,000 as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Common Stock	COMMON STOCK In January 2014, the Company entered into a securities purchase agreement with certain investors pursuant to which the Company sold an aggregate of 6,250,000 shares of its common stock at a purchase price of $6.00 per share. Gross proceeds from the offering were $37,500,000 prior to the payment of approximately $2,389,000 of related issuance costs. Proceeds from the private placement were used for general corporate and working capital purposes. In April 2014, 2,255,639 shares of common stock were issued pursuant to the conversion of 150,000 shares of Series A Convertible Preferred Stock held by an investor. In September 2014, 3,759,398 shares of common stock were issued pursuant to the conversion of 250,000 shares of Series A Convertible Preferred Stock held by another investor. During the nine months ended September 30, 2015 and 2014, 10,993 and 23,487 shares of the Company’s common stock were acquired through its employee stock purchase plan resulting in proceeds of $42,000 and $43,000 , respectively.

Stock Incentive Plans

Stock Incentive Plans	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Incentive Plans	STOCK INCENTIVE PLANS Stock Option Plans During the three months ended September 30, 2015 and 2014, the Company recorded compensation expense related to stock options of approximately $1,355,000 and $970,000 , respectively. During the nine months ended September 30, 2015 and 2014, the Company recorded compensation expense related to stock options of approximately $3,623,000 and $2,799,000 , respectively. As of September 30, 2015, the total unrecognized compensation cost related to non-vested stock options granted was $10,496,000 and is expected to be recognized over a weighted average period of 2.93 years . The following table presents a summary of stock option activity for the three and nine months ended September 30, 2015 and 2014: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 9,292,947 $ 3.49 7,599,768 $ 2.89 7,681,256 $ 3.03 7,566,438 $ 2.74 Grants 69,000 4.39 165,000 5.66 1,902,500 5.38 480,000 5.66 Forfeitures (200,260 ) 5.25 (10,208 ) 3.45 (349,645 ) 4.84 (109,375 ) 2.62 Exercises (66,971 ) 2.09 (172,098 ) 2.18 (139,395 ) 1.99 (354,601 ) 2.00 Options outstanding at period end 9,094,716 3.47 7,582,462 2.96 9,094,716 3.47 7,582,462 2.96 Options exercisable at period end 5,510,064 3.19 4,148,647 3.18 5,510,064 3.19 4,148,647 3.18 Weighted average per share fair value of options granted during the period $ 3.37 $ 4.55 $ 4.19 $ 4.71 The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of September 30, 2015 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 9,094,716 $ 3.47 6.86 years $ 2,025 Exercisable 5,510,064 3.19 5.72 years 1,699 Outstanding, vested and expected to vest 8,672,753 3.43 6.77 years 2,006 The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of December 31, 2014 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 7,681,256 $ 3.03 7.05 years $ 21,710 Exercisable 4,452,274 3.17 5.87 years 12,887 Outstanding, vested and expected to vest 7,258,603 3.04 6.95 years 20,574 Employee Stock Purchase Plan During the three months ended September 30, 2015 and 2014, the Company recorded compensation expense related to its employee stock purchase plan of approximately $38,000 and $14,000 , respectively. During the nine months ended September 30, 2015 and 2014, the Company recorded compensation expense related to its employee stock purchase plan of approximately and $79,000 and $35,000 , respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES In accordance with ASC 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company’s best estimate of operating results and foreign currency exchange rates. The Company’s quarterly income tax rate may differ from its estimated annual effective tax rate because accounting standards require the Company to exclude the actual results of certain entities expected to generate a pretax loss when applying the estimated annual effective tax rate to the Company’s consolidated pretax results in interim periods. In estimating the annual effective tax rate, the Company does not include the estimated impact of unusual and/or infrequent items, including the reversal of valuation allowances, which may cause significant variations in the customary relationship between income tax expense (benefit) and pretax income (loss) in quarterly periods. The income tax expense (benefit) for such unusual and/or infrequent items is recorded in the quarterly period such items are incurred. The Company’s income tax expense and resulting effective tax rate are based upon the respective estimated annual effective tax rates applicable for the respective periods adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Company’s effective tax rate for the three months ended September 30, 2015 properly excluded tax benefits associated with year-to-date pre-tax losses generated in the U.S. and the Netherlands. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company believes that its income tax filing positions and deductions are more likely than not to be sustained on audit; therefore, no ASC 740-10 liabilities and no related penalties and interest have been recorded. The Company does not anticipate any material changes to its uncertain tax positions within the next 12 months. Tax years since 2003 remain subject to examination in Georgia, Tennessee, and at the federal level. The time period is longer than the standard statutory 3-year period due to net operating losses (NOLs) from 2003 being available for utilization. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Tax years since 2012 remain subject to examination in the United Kingdom and the Netherlands. Tax years since 2013 remain subject to examination in Germany. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the entire net deferred tax asset balance. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact its financial position and results of operations. At December 31, 2014, the Company had federal NOL carry-forwards of approximately $89,547,000 and state NOL carry-forwards of approximately $72,968,000 available to reduce future income. The Company’s federal NOL carry-forwards remain fully reserved as of September 30, 2015. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2033 and the state NOL carry-forwards will expire at various dates between 2020 and 2033. The Company’s NOL carry-forwards may be subject to annual limitations under Internal Revenue Code (IRC) Section 382 (or comparable provisions of state law) in the event that certain changes in ownership of the Company were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership, including its IPO, have occurred that would limit its ability to utilize a portion of the Company’s NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, the Company may be subject to annual limitations on the use of these NOL carry-forwards under IRC Section 382 (or comparable provisions of state law). As of December 31, 2014, the Company had cumulative book losses in foreign subsidiaries of $42,795,000 . The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company has not recorded a deferred tax liability related to excess of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25.

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value	FAIR VALUE The Company applies ASC 820, Fair Value Measurements , in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows: Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. There have been no changes in the methodologies used at September 30, 2015 and December 31, 2014. The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: September 30, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 2,510 $ — $ — $ 2,510 Assets measured at fair value $ 2,510 $ — $ — $ 2,510 Liabilities: Derivative warrant liability (2) $ — $ 3,013 $ — $ 3,013 Liabilities measured at fair value $ — $ 3,013 $ — $ 3,013 December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 65,509 $ — $ — $ 65,509 Assets measured at fair value $ 65,509 $ — $ — $ 65,509 Liabilities: Derivative warrant liability (2) $ — $ 16,098 $ — $ 16,098 Liabilities measured at fair value $ — $ 16,098 $ — $ 16,098 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The following table presents a summary of the Company's reporting segments for the three months ended September 30, 2015 and 2014: Three Months Ended Three Months Ended U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 5,032 $ 1,869 $ 6,901 $ — $ 2,408 $ 2,408 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (245 ) (389 ) (634 ) — (372 ) (372 ) GROSS PROFIT 4,787 1,480 6,267 — 2,036 2,036 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 2,320 1,758 4,078 2,595 1,550 4,145 GENERAL AND ADMINISTRATIVE EXPENSES 1,712 1,319 3,031 1,788 1,170 2,958 SALES AND MARKETING EXPENSES 4,546 2,403 6,949 1,186 2,290 3,476 DEPRECIATION AND AMORTIZATION 639 14 653 82 — 82 OPERATING EXPENSES 9,217 5,494 14,711 5,651 5,010 10,661 NET LOSS FROM OPERATIONS (4,430 ) (4,014 ) (8,444 ) (5,651 ) (2,974 ) (8,625 ) OTHER INCOME AND EXPENSES, NET 6,983 1,661 NET LOSS BEFORE TAXES $ (1,461 ) $ (6,964 ) The following table presents a summary of the Company's reporting segments for the nine months ended September 30, 2015 and 2014: Nine Months Ended Nine Months Ended U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 11,279 $ 5,336 $ 16,615 $ — $ 6,682 $ 6,682 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (573 ) (720 ) (1,293 ) — (1,312 ) (1,312 ) GROSS PROFIT 10,706 4,616 15,322 — 5,370 5,370 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 5,176 6,046 11,222 4,136 4,704 8,840 GENERAL AND ADMINISTRATIVE EXPENSES 6,080 4,391 10,471 5,103 3,540 8,643 SALES AND MARKETING EXPENSES 14,274 6,729 21,003 1,968 7,795 9,763 DEPRECIATION AND AMORTIZATION 1,819 45 1,864 151 — 151 OPERATING EXPENSES 27,349 17,211 44,560 11,358 16,039 27,397 NET LOSS FROM OPERATIONS (16,643 ) (12,595 ) (29,238 ) (11,358 ) (10,669 ) (22,027 ) OTHER INCOME AND EXPENSES, NET 9,461 (4,511 ) NET LOSS BEFORE TAXES $ (19,777 ) $ (26,538 )

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENT As disclosed in Note 9, the Company entered into the first amendment to its 2014 Loan Agreement with Hercules in November 2015. The specific terms of the amendment are disclosed in detail Note 9.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition In the U.S., the Company sells ILUVIEN to a limited number of specialty distributors who in turn sell the product downstream to pharmacies and physician practices. Revenue from U.S. product sales is recorded upon sale to the specialty distributors net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period’s net product sales. Government Rebates and Chargebacks: The Company estimates reductions to product sales for Medicaid and Veterans’ Administration (VA) programs, and for certain other qualifying federal and state government programs. Based upon the Company’s contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company’s liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company’s reserves related to discounted pricing to VA, Public Health Services, and other institutions (collectively qualified healthcare providers) represent the Company’s estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., specialty distributors). The Company’s customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company’s reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. Distribution-Related Fees: The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. Product Returns: Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product’s expiration date. The Company will accept returns for three months prior to and up to nine months after the product expiration date. Depending on the circumstances, the Company may provide replacement products or cash credit for returns. Product returned is generally not resalable given the nature of the Company’s products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers to healthcare providers using product-specific data provided by its customers. If necessary, the Company’s estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.
Reporting Segments	Reporting Segments The Company determines operating segments in accordance with its internal operating structure. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon net loss from operations. The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision maker. The Company has two reportable segments, the U.S. and International. Previously, the business was managed on an aggregate basis. As a result of the retrospective presentation and disclosure requirements under U.S. GAAP for changes in segment reporting, the Company is required to reflect the change in presentation and disclosure for all periods presented. As such, the Company has presented in Note 16, Segment Information, the financial results for the three and nine months ended September 30, 2014 in the same manner as for the three and nine months ended September 30, 2015. During the three and nine months ended September 30, 2015, two individual customers within the U.S. segment accounted for 73% and 68% of the Company's consolidated revenues. As of September 30, 2015, two individual customers within the U.S. segment accounted for 83% of the Company's accounts receivable balances. The accounting policies of these segments are the same as those described in Note 2, Summary of Significant Accounting Policies included in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU 2014-09 provides a single, comprehensive revenue recognition model for all contracts with customers. The revenue guidance contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The standard is effective for the first interim period within annual reporting periods beginning after December 15, 2017 for public entities, with early adoption permitted in the annual reporting period beginning after December 15, 2016. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern . ASU 2014-15 provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company is still evaluating the potential impact of adopting this guidance on its financial statements. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 is intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted and the standard is to be retrospectively applied to all periods presented upon adoption. The Company is still evaluating the potential impact of adopting this guidance on its financial statements.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following: September 30, 2015 December 31, 2014 (In thousands) Component parts (1) $ 153 $ 76 Work-in-process (2) 693 219 Finished goods 1,185 1,972 Total inventory 2,031 2,267 Inventory reserve (315 ) (533 ) Inventory — net $ 1,716 $ 1,734 (1) Component parts inventory consists of manufactured components of the ILUVIEN applicator. (2) Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization expense as of September 30, 2015 for the remaining periods in the next five years and thereafter is as follows (in thousands): Years Ending December 31 2015 $ 488 2016 1,940 2017 1,940 2018 1,940 2019 1,940 Thereafter 14,790 Total $ 23,038

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following: September 30, 2015 December 31, 2014 (In thousands) Accrued compensation expenses $ 1,718 $ 226 Accrued clinical investigator expenses 453 309 Accrued rebate, chargeback and other revenue reserves 402 — Other accrued expenses 665 419 Total accrued expenses $ 3,238 $ 954

Loss Per Share (EPS) (Tables)

Loss Per Share (EPS) (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of antidilutive securities excluded from computation of earnings per share	Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Three Months Ended September 30, Nine Months Ended 2015 2014 2015 2014 Series A convertible preferred stock 9,022,556 9,022,556 9,022,556 9,022,556 Series B convertible preferred stock 8,416,251 — 8,416,251 — Series A convertible preferred stock warrants 4,511,279 4,511,279 4,511,279 4,511,279 Common stock warrants 362,970 362,970 362,970 362,970 Stock options 9,094,716 7,582,462 9,094,716 7,582,462 Total 31,407,772 21,479,267 31,407,772 21,479,267

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock option transactions	The following table presents a summary of stock option activity for the three and nine months ended September 30, 2015 and 2014: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 9,292,947 $ 3.49 7,599,768 $ 2.89 7,681,256 $ 3.03 7,566,438 $ 2.74 Grants 69,000 4.39 165,000 5.66 1,902,500 5.38 480,000 5.66 Forfeitures (200,260 ) 5.25 (10,208 ) 3.45 (349,645 ) 4.84 (109,375 ) 2.62 Exercises (66,971 ) 2.09 (172,098 ) 2.18 (139,395 ) 1.99 (354,601 ) 2.00 Options outstanding at period end 9,094,716 3.47 7,582,462 2.96 9,094,716 3.47 7,582,462 2.96 Options exercisable at period end 5,510,064 3.19 4,148,647 3.18 5,510,064 3.19 4,148,647 3.18 Weighted average per share fair value of options granted during the period $ 3.37 $ 4.55 $ 4.19 $ 4.71
Summary of additional stock option transactions	The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of September 30, 2015 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 9,094,716 $ 3.47 6.86 years $ 2,025 Exercisable 5,510,064 3.19 5.72 years 1,699 Outstanding, vested and expected to vest 8,672,753 3.43 6.77 years 2,006 The following table provides additional information related to outstanding stock options, exercisable stock options, and stock options expected to vest as of December 31, 2014 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 7,681,256 $ 3.03 7.05 years $ 21,710 Exercisable 4,452,274 3.17 5.87 years 12,887 Outstanding, vested and expected to vest 7,258,603 3.04 6.95 years 20,574

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value on Recurring Basis	The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: September 30, 2015 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 2,510 $ — $ — $ 2,510 Assets measured at fair value $ 2,510 $ — $ — $ 2,510 Liabilities: Derivative warrant liability (2) $ — $ 3,013 $ — $ 3,013 Liabilities measured at fair value $ — $ 3,013 $ — $ 3,013 December 31, 2014 Level 1 Level 2 Level 3 Total (In thousands) Assets: Cash equivalents (1) $ 65,509 $ — $ — $ 65,509 Assets measured at fair value $ 65,509 $ — $ — $ 65,509 Liabilities: Derivative warrant liability (2) $ — $ 16,098 $ — $ 16,098 Liabilities measured at fair value $ — $ 16,098 $ — $ 16,098 (1) The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents. (2) The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of Reporting Segments	The following table presents a summary of the Company's reporting segments for the three months ended September 30, 2015 and 2014: Three Months Ended Three Months Ended U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 5,032 $ 1,869 $ 6,901 $ — $ 2,408 $ 2,408 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (245 ) (389 ) (634 ) — (372 ) (372 ) GROSS PROFIT 4,787 1,480 6,267 — 2,036 2,036 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 2,320 1,758 4,078 2,595 1,550 4,145 GENERAL AND ADMINISTRATIVE EXPENSES 1,712 1,319 3,031 1,788 1,170 2,958 SALES AND MARKETING EXPENSES 4,546 2,403 6,949 1,186 2,290 3,476 DEPRECIATION AND AMORTIZATION 639 14 653 82 — 82 OPERATING EXPENSES 9,217 5,494 14,711 5,651 5,010 10,661 NET LOSS FROM OPERATIONS (4,430 ) (4,014 ) (8,444 ) (5,651 ) (2,974 ) (8,625 ) OTHER INCOME AND EXPENSES, NET 6,983 1,661 NET LOSS BEFORE TAXES $ (1,461 ) $ (6,964 ) The following table presents a summary of the Company's reporting segments for the nine months ended September 30, 2015 and 2014: Nine Months Ended Nine Months Ended U.S. International Consolidated U.S. International Consolidated (In thousands) NET REVENUE $ 11,279 $ 5,336 $ 16,615 $ — $ 6,682 $ 6,682 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (573 ) (720 ) (1,293 ) — (1,312 ) (1,312 ) GROSS PROFIT 10,706 4,616 15,322 — 5,370 5,370 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 5,176 6,046 11,222 4,136 4,704 8,840 GENERAL AND ADMINISTRATIVE EXPENSES 6,080 4,391 10,471 5,103 3,540 8,643 SALES AND MARKETING EXPENSES 14,274 6,729 21,003 1,968 7,795 9,763 DEPRECIATION AND AMORTIZATION 1,819 45 1,864 151 — 151 OPERATING EXPENSES 27,349 17,211 44,560 11,358 16,039 27,397 NET LOSS FROM OPERATIONS (16,643 ) (12,595 ) (29,238 ) (11,358 ) (10,669 ) (22,027 ) OTHER INCOME AND EXPENSES, NET 9,461 (4,511 ) NET LOSS BEFORE TAXES $ (19,777 ) $ (26,538 )

Nature of Operations (Detail)

Nature of Operations (Detail) - ILUVIEN	9 Months Ended
	Sep. 30, 2015Patient
Nature Of Operations [Line Items]
Post-authorization open study period (in years)	5 years
Planned drug study, number of patients	800

Basis of Presentation - Reclass

Basis of Presentation - Reclassifications (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Adjustment To Prior Period
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Employee expenses	$ 204	$ 464

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Segmentcustomer	Sep. 30, 2014USD ($)
Accounting Policies [Abstract]
Number of reportable segments | Segment			2
Concentration Risk [Line Items]
Research and development expense | $	$ 940	$ 1,082	$ 1,958	$ 3,480
U.S. | Customer concentration risk | Accounts Receivable
Concentration Risk [Line Items]
Number of customers accounting for significant amount of activity			2,000
Concentration percentage			83.00%
U.S. | Customer concentration risk | Consolidated revenues
Concentration Risk [Line Items]
Number of customers accounting for significant amount of activity			2
Concentration percentage	73.00%		68.00%

Factors Affecting Operations (D

Factors Affecting Operations (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (333,187)	$ (313,255)
Cash and cash equivalents	$ 39,340	$ 76,697	$ 61,424	$ 12,628

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands		Sep. 30, 2015	Dec. 31, 2014
Inventory net realizable value
Component parts	[1]	$ 153	$ 76
Work-in-process	[2]	693	219
Finished goods		1,185	1,972
Total inventory		2,031	2,267
Inventory reserve		(315)	(533)
Inventory — net		$ 1,716	$ 1,734
[1]	Component parts inventory consists of manufactured components of the ILUVIEN applicator.
[2]	Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing as required by regulatory authorities.

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Aug. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Net intangible assets		$ 23,038,000		$ 23,038,000		$ 24,490,000	$ 0
License
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets		25,000,000		$ 25,000,000
Useful life (in years)				13 years
Amortization of intangible assets		489,000	$ 49,000	$ 1,451,000	$ 49,000
Net intangible assets		$ 23,038,000		$ 23,038,000		$ 24,490,000
pSivida
Finite-Lived Intangible Assets [Line Items]
Milestone payment after the first product approved by the FDA	$ 25,000,000

Intangible Assets - Future Amor

Intangible Assets - Future Amortization (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Aug. 31, 2014
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	$ 23,038,000	$ 24,490,000	$ 0
License
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2,015	488,000
2,016	1,940,000
2,017	1,940,000
2,018	1,940,000
2,019	1,940,000
Thereafter	14,790,000
Total	$ 23,038,000	$ 24,490,000

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Summary of accrued expenses
Accrued compensation expenses	$ 1,718	$ 226
Accrued clinical investigator expenses	453	309
Accrued rebate, chargeback and other revenue reserves	402	0
Other accrued expenses	665	419
Total accrued expenses	$ 3,238	$ 954

License Agreements (Detail)

License Agreements (Detail) - pSivida - USD ($)	1 Months Ended	9 Months Ended
	Oct. 31, 2014	Sep. 30, 2015	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Minimum days to require to revert license in case of breaches of contract		30 days
Maximum days to require to revert license in case of breaches of contract		90 days
Period of bankruptcy petition proceedings remains undismissed (in days)		60 days
Share of net profits (percent)		20.00%
Share of any lump sum milestone payments received from a sub-licensee of ILUVIEN (percent)		33.00%
Recovery of commercialization costs (percent)		20.00%
Commercialization costs owed		$ 19,997,000	$ 12,956,000
Additional milestone payment after the first product approved by the FDA	$ 25,000,000

Loan Agreements - Additional In

Loan Agreements - Additional Information (Detail)	1 Months Ended
	Nov. 30, 2015USD ($)payment$ / sharesshares	Sep. 30, 2014USD ($)	Apr. 30, 2014USD ($)$ / sharesshares	May. 31, 2013USD ($)
Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | 2014 Term Loan
Debt Instrument [Line Items]
Increase of term loan		$ 25,000,000
Number of shares called by warrants | shares			285,016
Exercise price on warrants (in dollars per share) | $ / shares			$ 6.14
Warrants exercisable (percent)			60.00%
Warrants that will become exercisable upon obtaining additional financing amount (percent)			40.00%
Alimera Sciences Limited (Limited) | Silicon Valley Bank (SVB) | 2013 Term Loan
Debt Instrument [Line Items]
Term loan amount				$ 5,000,000
Prepayment fee			$ 133,000
Alimera Sciences Limited (Limited) | Silicon Valley Bank (SVB) | 2013 Line of Credit
Debt Instrument [Line Items]
Company entitled to borrow				$ 15,000,000
Termination fee amount			113,000
Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | 2014 Term Loan
Debt Instrument [Line Items]
Term loan amount			10,000,000
Company entitled to borrow			$ 35,000,000
Increase of term loan		25,000,000
Interest rate on term loan (percent)			10.90%
Basis spread on variable rate (percent)			7.65%
Debt issuance costs incurred		$ 375,000	$ 383,000
Prepayment fee percentage within the first year of borrowing			1.25%
Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | 2015 Loan Amendment
Debt Instrument [Line Items]
An upfront fee payment to lenders			$ 262,500
Subsequent Event | Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | 2015 Loan Amendment
Debt Instrument [Line Items]
Number of shares called by warrants | shares	660,377
Exercise price on warrants (in dollars per share) | $ / shares	$ 2.65
Subsequent Event | Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | 2015 Loan Amendment
Debt Instrument [Line Items]
Number of payments required under instrument terms | payment	11
Amortization period (in months)	30 months
Additional payment to be made	$ 1,050,000
Additional payment to be made, percentage of principal	3.00%

Loss Per Share (EPS) - AntiDilu

Loss Per Share (EPS) - AntiDilutive Securities Excluded (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	31,407,772	21,479,267	31,407,772	21,479,267
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	9,022,556	9,022,556	9,022,556	9,022,556
Series B convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	8,416,251	0	8,416,251	0
Series A convertible preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	4,511,279	4,511,279	4,511,279	4,511,279
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	362,970	362,970	362,970	362,970
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	9,094,716	7,582,462	9,094,716	7,582,462

Preferred Stock (Detail)

Preferred Stock (Detail) - USD ($)	Dec. 12, 2014	Oct. 02, 2012	Sep. 30, 2014	Apr. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Conversion of Stock [Line Items]
Estimated fair value of derivatives					$ 3,013,000		$ 3,013,000		$ 16,098,000
Gain (loss) on change in fair value of derivatives					$ 8,363,000	$ 2,324,000	13,085,000	$ (2,752,000)
Payment of stock issuance cost							$ 0	$ 2,389,000
Series A convertible preferred stock
Conversion of Stock [Line Items]
Number of preferred stock and warrants (in shares)		1,000,000
Warrants to purchase additional shares		300,000
Gross proceeds under securities purchase agreement		$ 40,000,000
Estimated total stock issuance cost		$ 560,000
Conversion rate of Series A Convertible Preferred Stock issued upon exercise of warrants into common stock (in dollar per share)		$ 40
Initial conversion price (in dollars per share)		2.66
Preferred stock converted to common stock per share (in dollars per share)		$ 10
Proceeds from issuance of preferred stock		$ 30,000,000
Proportion of each unit of shares (in shares)		0.30
Exercise price of warrants (in dollars per share)		$ 44
Convertible securities converted (in shares)			250,000	150,000
Preferred stock, shares issued					600,000		600,000		600,000
Preferred stock, shares outstanding					600,000		600,000		600,000
Common stock
Conversion of Stock [Line Items]
Common stock issued upon conversion of convertible securities (in shares)			3,759,398	2,255,639
Series B convertible preferred stock
Conversion of Stock [Line Items]
Preferred stock, shares issued					8,416.251		8,416.251		8,416.251
Preferred stock, shares outstanding					8,416.251		8,416.251		8,416.251
Issuance of stock (in shares)	8,291.873
Share purchase price of shares issued (in dollars per share)	$ 6,030
Stock issued during period (in shares)	$ 50,000,000
Payment of stock issuance cost	$ 432,000
Shares issued upon conversion	1,000
Ownership interest after conversion (percent)	9.98%
Adjustment to APIC									$ 750,000
Series B convertible preferred stock | Over-Allotment Option
Conversion of Stock [Line Items]
Issuance of stock (in shares)	124.378

Common Stock (Detail)

Common Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			9 Months Ended
	Sep. 30, 2014	Apr. 30, 2014	Jan. 31, 2014	Sep. 30, 2015	Sep. 30, 2014
Class of Stock [Line Items]
Proceeds from sale of common stock				$ 42	$ 37,543
Payment of stock issuance cost				0	2,389
Common stock
Class of Stock [Line Items]
Common stock issued upon conversion of convertible securities	3,759,398	2,255,639
Series A convertible preferred stock
Class of Stock [Line Items]
Convertible securities converted	250,000	150,000
Private placement | Common stock
Class of Stock [Line Items]
Issuance of stock (in shares)			6,250,000
Share purchase price of shares issued (in dollars per share)			$ 6
Proceeds from sale of common stock			$ 37,500
Payment of stock issuance cost			$ 2,389
Employee Stock | Common stock
Class of Stock [Line Items]
Proceeds from sale of common stock				$ 42	$ 43
Shares issued				10,993	23,487

Stock Incentive Plans - Additio

Stock Incentive Plans - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual term (years)			5 years 8 months 19 days		5 years 10 months 13 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 1,355	$ 970	$ 3,623	$ 2,799
Share-based compensation not yet recognized	10,496		$ 10,496
Weighted average contractual term (years)			2 years 11 months 4 days
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 38	$ 14	$ 79	$ 35

Stock Incentive Plans - Summary

Stock Incentive Plans - Summary of Stock Option Transactions (Detail) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Options
Options outstanding at beginning of period (in shares)	9,292,947	7,599,768	7,681,256	7,566,438
Grants (in shares)	69,000	165,000	1,902,500	480,000
Forfeitures (in shares)	(200,260)	(10,208)	(349,645)	(109,375)
Exercises (in shares)	(66,971)	(172,098)	(139,395)	(354,601)
Options outstanding at year end (in shares)	9,094,716	7,582,462	9,094,716	7,582,462
Options exercisable at year end (in shares)	5,510,064	4,148,647	5,510,064	4,148,647	4,452,274
Weighted average per share fair value of options granted during the period (in dollars per share)	$ 3.37	$ 4.55	$ 4.19	$ 4.71
Weighted Average Exercise Price
Options outstanding at beginning of period (in dollars per share)	3.49	2.89	3.03	2.74
Grants (in dollars per share)	4.39	5.66	5.38	5.66
Forfeitures (in dollars per share)	5.25	3.45	4.84	2.62
Exercises (in dollars per share)	2.09	2.18	1.99	2
Options outstanding at year end (in dollars per share)	3.47	2.96	3.47	2.96
Options exercisable at year end (in dollars per share)	$ 3.19	$ 3.18	$ 3.19	$ 3.18	$ 3.17

Stock Incentive Plans - Addit47

Stock Incentive Plans - Additional Stock Option Transactions (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Jun. 30, 2015	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
Outstanding Stock Options
Outstanding, Shares	9,094,716	7,681,256	9,292,947	7,582,462	7,599,768	7,566,438
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.47	$ 3.03	$ 3.49	$ 2.96	$ 2.89	$ 2.74
Outstanding, Weighted Average Contractual Term (years)	6 years 10 months 9 days	7 years 18 days
Outstanding, Aggregate Intrinsic Value	$ 2,025	$ 21,710
Exercisable Stock Options
Exercisable, Shares	5,510,064	4,452,274		4,148,647
Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.19	$ 3.17		$ 3.18
Exercisable, Weighted Average Contractual Term (years)	5 years 8 months 19 days	5 years 10 months 13 days
Exercisable, Aggregate Intrinsic Value	$ 1,699	$ 12,887
Exercisable and expected to vest
Outstanding, vested and expected to vest, Shares	8,672,753	7,258,603
Outstanding, vested and expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 3.43	$ 3.04
Outstanding, vested and expected to vest, Weighted Average Contractual Term (years)	6 years 9 months 7 days	6 years 11 months 12 days
Outstanding, vested and expected to vest, Aggregate Intrinsic Value	$ 2,006	$ 20,574

Income Taxes (Detail)

Income Taxes (Detail) $ in Thousands	Dec. 31, 2014USD ($)
Operating Loss Carryforwards [Line Items]
Cumulative book losses in foreign subsidiaries	$ (42,795)
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	89,547
State
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	$ 72,968

Fair Value - Assets Measured at

Fair Value - Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring basis - USD ($) $ in Thousands		Sep. 30, 2015	Dec. 31, 2014
Assets:
Cash equivalents	[1]	$ 2,510	$ 65,509
Assets measured at fair value		2,510	65,509
Liabilities:
Derivative warrant liability	[2]	3,013	16,098
Liabilities measured at fair value		3,013	16,098
Level 1
Assets:
Cash equivalents	[1]	2,510	65,509
Assets measured at fair value		2,510	65,509
Liabilities:
Derivative warrant liability	[2]	0	0
Liabilities measured at fair value		0	0
Level 2
Assets:
Cash equivalents	[1]	0	0
Assets measured at fair value		0	0
Liabilities:
Derivative warrant liability	[2]	3,013	16,098
Liabilities measured at fair value		3,013	16,098
Level 3
Assets:
Cash equivalents	[1]	0	0
Assets measured at fair value		0	0
Liabilities:
Derivative warrant liability	[2]	0	0
Liabilities measured at fair value		$ 0	$ 0
[1]	The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.
[2]	The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments.

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
NET REVENUE	$ 6,901	$ 2,408	$ 16,615	$ 6,682
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(634)	(372)	(1,293)	(1,312)
GROSS PROFIT	6,267	2,036	15,322	5,370
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	4,078	4,145	11,222	8,840
GENERAL AND ADMINISTRATIVE EXPENSES	3,031	2,958	10,471	8,643
SALES AND MARKETING EXPENSES	6,949	3,476	21,003	9,763
DEPRECIATION AND AMORTIZATION	653	82	1,864	151
OPERATING EXPENSES	14,711	10,661	44,560	27,397
NET LOSS FROM OPERATIONS	(8,444)	(8,625)	(29,238)	(22,027)
OTHER INCOME AND EXPENSES, NET	6,983	1,661	9,461	(4,511)
NET LOSS BEFORE TAXES	(1,461)	(6,964)	(19,777)	(26,538)
U.S.
Segment Reporting Information [Line Items]
NET REVENUE	5,032	0	11,279	0
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(245)	0	(573)	0
GROSS PROFIT	4,787	0	10,706	0
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	2,320	2,595	5,176	4,136
GENERAL AND ADMINISTRATIVE EXPENSES	1,712	1,788	6,080	5,103
SALES AND MARKETING EXPENSES	4,546	1,186	14,274	1,968
DEPRECIATION AND AMORTIZATION	639	82	1,819	151
OPERATING EXPENSES	9,217	5,651	27,349	11,358
NET LOSS FROM OPERATIONS	(4,430)	(5,651)	(16,643)	(11,358)
International
Segment Reporting Information [Line Items]
NET REVENUE	1,869	2,408	5,336	6,682
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(389)	(372)	(720)	(1,312)
GROSS PROFIT	1,480	2,036	4,616	5,370
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,758	1,550	6,046	4,704
GENERAL AND ADMINISTRATIVE EXPENSES	1,319	1,170	4,391	3,540
SALES AND MARKETING EXPENSES	2,403	2,290	6,729	7,795
DEPRECIATION AND AMORTIZATION	14	0	45	0
OPERATING EXPENSES	5,494	5,010	17,211	16,039
NET LOSS FROM OPERATIONS	$ (4,014)	$ (2,974)	$ (12,595)	$ (10,669)